Metaphedrine
Designer drug
From Wikipedia, the free encyclopedia
3-Methylmethamphetamine (3-MMA or 3-Me-MA), also known as metaphedrine, is an amphetamine derivative which has been sold as a designer drug, first encountered online in 2020 and reported in Sweden in 2021.[1][2] It is a potent monoamine reuptake inhibitor[3] and is thought to have psychostimulant effects.[2] The drug was not active as a serotonin 5-HT2A receptor agonist.[3]
Other names3-Methyl-N-methylamphetamine; 3-MMA; 3MMA; 3-Me-MA; Metaphedrine
| Clinical data | |
|---|---|
| Other names | 3-Methyl-N-methylamphetamine; 3-MMA; 3MMA; 3-Me-MA; Metaphedrine |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H17N |
| Molar mass | 163.264 g·mol−1 |
| 3D model (JSmol) | |
| |
| |